Bladder cancer is the sixth cause of cancer mortality in France and prognosis of muscle-invasive tumors remains poor due to lack of effective treatments. Recent advances in molecular biology applied to tumors and results of recent genome-wide studies have brought a important impact on the understanding of bladder carcinogenesis. Main molecular alterations concern FGFR3, TP53 and HER2, and it is now possible to distinguish three subgroups of tumors according to molecular profile. This paper proposes a review of different genetic and epigenetic alterations in bladder cancer, their potential role as theranostic markers in clinical oncology and new targeted therapies according to the concept of personalized medicine.
Keywords: Bladder cancer; Carcinogenesis; Carcinogenèse; Marqueurs moléculaires; Molecular markers; Targeted therapies; Thérapies ciblées; Tumeur de vessie.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.